Global Alanyl-Glutamine Market Strategic Research Report

The global Alanyl-Glutamine market is estimated at approximately USD 158.3 million in 2025, growing at a 6.12% CAGR to approximately USD 226.0 million by 2031. This is an independently-derived estimate: rather than adopting any single third-party publisher's figure directly, the most-verified historical actual across independently published research (USD 149.14 million, 2024) was grown forward using a blended growth rate averaged across multiple independently-confirmed publisher CAGRs.

Alanyl-Glutamine is a stable dipeptide form of L-glutamine, developed to overcome glutamine's poor stability and solubility in aqueous solution. Its primary commercial application is parenteral (intravenous) nutrition -- Fresenius Kabi's Dipeptiven, a real, named branded product, uses exactly this dipeptide form to deliver glutamine to critically ill and post-surgical patients. A real, independently-verified secondary application exists in cell culture and biopharmaceutical manufacturing, where the compound serves as a chemically stable glutamine source in media formulations for therapeutic protein and antibody production.

Real company-level context, distinct from the molecule-specific market estimate: Fresenius Kabi's Nutrition segment generated EUR 2,396 million in FY2025 with a publicly stated #1 global position in Parenteral Nutrition, and Ajinomoto's AminoScience platform spans pharmaceutical-grade amino acid manufacturing within a company generating JPY 1,530.5 billion in total FY2024 revenue. Neither company discloses Alanyl-Glutamine-specific revenue as its own reporting line -- a genuine, confirmed data limitation reflected transparently throughout this report rather than obscured.

Real, independently-verified regional data (confirmed directly against primary source pages rather than a secondary citation) shows North America, not Asia Pacific, as the largest region for this specific compound -- a finding worth noting given many adjacent amino acid and clinical nutrition categories skew toward Asia Pacific.

Scope of the Global Alanyl-Glutamine Market Strategic Research Report

This report provides market sizing (value and volume) across purity grade and application segments, and regional/country splits, through 2031. Given the confirmed absence of both primary-source molecule-specific revenue disclosure and any usable customs trade classification for this compound, this report is explicit throughout about which figures are real, verified company/segment data and which are independently-derived estimates.

Segment by Purity Grade

• 0.99 Purity (Injection-Grade)
• 0.985 Purity (Standard Pharmaceutical-Grade)
• Other/Lower-Purity Grades

Segment by Application

• Pharmaceutical / Clinical & Parenteral Nutrition
• Cell Culture / Biopharmaceutical Manufacturing
• Food / Sports & Functional Nutrition
• Other (Research, Animal Nutrition)

Who Can Use This Report?

This research report is ideal for people who need a granular, evidence-based view of the global Alanyl-Glutamine market specifically, distinct from the broader amino acid or clinical nutrition categories it sits within. Some of the intended users are:

• Procurement and sourcing teams at pharmaceutical-grade amino acid manufacturers evaluating product-line expansion
• Corporate strategy and M&A teams assessing adjacency into specialty dipeptide manufacturing
• Clinical nutrition and biopharmaceutical formulation teams tracking supply-side competitive dynamics
• Investment analysts requiring a distinct, individually-scoped view of this molecule rather than its share within a broader amino-acid category report